The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct
Article first published online: 23 JAN 2007
Volume 121, Issue 1, pages 140–145, May 2007
How to Cite
Cole, A. L., Herasimtschuk, A., Gupta, P., Waring, A. J., Lehrer, R. I. and Cole, A. M. (2007), The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct. Immunology, 121: 140–145. doi: 10.1111/j.1365-2567.2006.02553.x
- Issue published online: 23 JAN 2007
- Article first published online: 23 JAN 2007
- Received 5 September 2006; revised 27 November 2006; accepted 28 November 2006.
- antimicrobial peptide;
- human immunodeficiency virus;
- acquired immunodeficieny syndrome;
Retrocyclins are cyclic antimicrobial peptides that exhibit potent activity towards a broad range of primary and laboratory-adapted strains of human immunodeficiency virus type 1 (HIV-1) in vitro. The current study shows that RC-101, an analogue of retrocyclin, prevented HIV-1 infection in an organ-like construct of human cervicovaginal tissue and retained full activity in the presence of vaginal fluid. The peptide remained within the cervicovaginal tissues throughout the 9-day incubation period without altering tissue viability, inducing damage or inducing the release of inflammatory cytokines. Collectively, these data support the potential development of RC-101 as a topical microbicide to prevent HIV-1 infection and transmission.